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bstract
Response variability to antiplatelet treatment has been described and the widespread use of acetylsalicylic acid (ASA) and clopidogrel
equires clarification of the residual platelet reactivity (RPR). Various glycoprotein Ia (GpIa) polymorphisms have been investigated, but their
nfluence on platelet reactivity in myocardial infarction (MI) patients undergoing percutaneous coronary intervention (PCI) on dual antiplatelet
reatment is not still elucidated.
Aim of this study was to evaluate the effect of C807T, G873A and T837C polymorphisms of GpIa on modulating platelet function in MI
atients on dual antiplatelet treatment undergoing PCI.
We measured platelet function by both a point-of-care assay (PFA100) and platelet-rich-plasma aggregation in 289 MI patients undergoing
CI and receiving dual antiplatelet treatment.
Our data show that C807T/G873A polymorphisms, but not T837C, are associated with higher platelet reactivity. Carriers of the 807T/873A
llele had significantly higher platelet aggregation values after arachidonic acid (AA) and collagen stimuli and, even if they did not reach
he statistical significance, after 2 and 10M ADP stimuli; 807T/873A allele carriers had also significantly shorter closure times on
FA100/epinephrine membranes. At the multiple analyses, C807T/G873A polymorphisms resulted an independent risk factor for RPR defined
y both AA induced platelet aggregation (OR = 3.0, 95%CI 1.17–7.89, p = 0.022) or by PFA100/epinephrine (OR = 4.1, 95%CI 1.53–10.89,
= 0.005).
In conclusion, this study shows the 807T/873A allele of the GpIa gene is an independent risk factor for the RPR on dual antiplateletreatment, and extends, in a larger acute coronary syndrome population, the observation that the 807T/873A allele is associated with higher
latelet reactivity.
2006 Elsevier Ireland Ltd. All rights reserved.
eywords: Glycoprotein Ia polymorphisms; Residual platelet reactivity; Aspirin resistance; Antiplatelet treatment; Percutaneous coronary intervention
n. IntroductionAcetylsalicylic acid (ASA) and clopidogrel have become
tandard therapy in patients undergoing percutaneous coro-
∗ Corresponding author. Tel.: +39 055 794 9420; fax: +39 055 794 9418.
E-mail address: betti.giusti@unifi.it (B. Giusti).
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oi:10.1016/j.atherosclerosis.2006.11.009ary intervention (PCI); however, there is a broad variability
n response of individual patients to dual antiplatelet
reatment [1–5]. Previous studies estimated that adequate
ntiplatelet effects are not achieved in 5–45% of patients tak-
ng ASA and 4–30% of patients taking clopidogrel [1,3–6].
ome studies are available in the literature which investigated
he clinical implications of antiplatelet drug effect resistance
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Venous blood samples were taken from each patient 24 h
after PCI intervention in tubes containing 3.2% trisodium
citrate.
Table 1
Demographic and clinical characteristics of studied subjects
Age 67.5 (27–89)
Sex (M/F) 222/67
Hypertension 178 (61.6%)
Smoking habit 139 (48.1%)
Dyslipidemia 200 (69.2%)
Diabetes 61 (21.1%)42 B. Giusti et al. / Athero
n chronic coronary artery disease (CAD) or stent thrombo-
is [2,5,7–10]. Recently, we have demonstrated that post-PCI
esidual platelet reactivity (RPR), the so called ASA resis-
ance, is an independent predictor of 1-year major adverse
oronary events in patients with acute myocardial infarction
MI) [11].
Collagen is a major adhesion protein exposed to platelets
fter blood vessel injury [12]. Interaction between collagen
nd blood platelets results in their adhesion, activation and
ggregation, and finally in the formation of haemostatic plugs
13,14]. Platelets interact with collagen via several platelet
urface receptors, and major roles are attributed to glyco-
rotein Ia/IIa (GpIaIIa or 21 integrin) [15,16] as well as
lycoprotein VI [17]. GpIa/IIa is the major collagen receptor
nvolved in the early steps of platelet adhesion to collagen
nder high shear stress [14]. Previous studies showed that
pIa/IIa is activated by various agonists, including thrombin
r ADP, and that the activation of GpIa/IIa leads to a different
ffinity to collagen [13,18].
Several polymorphisms have been described in the cDNA
oding the GpIa subunit. The C807T, T837C and G873A
olymorphisms are conservative and do not alter the deduced
mino acid sequence of the translated protein. The two linked
ilent GpIa dimorphisms, C807T and G873A, were correlated
ith a variable expression of the platelet surface receptor: the
enotype 807TT/873AA was associated with a higher recep-
or density and the genotype 807CC/873GG with a lower
ensity, whereas heterozygous individuals expressed inter-
ediate receptor levels [19,20]. Differences in the receptor
ensity directly correlate with the rate of platelet adhesion to
ollagen under flow conditions [21]. The functional role of
he C807T GpIa polymorphism on modulating the response
o antiplatelet drugs in patients has been hypothesized in two
revious studies: one studying 44 patients undergoing PCI
uring the first 24 h following clopidogrel loading dose and
n ASA treatment for at least 7 days [22], and the other one
valuating 82 CAD patients on dual antiplatelet treatment
or >1 month [23]. Scarce data are available on T837C GpIa
olymorphism.
Therefore, the aim of this study was to assess the role
f the C807T, G873A, and T837C GpIa gene polymor-
hisms on modulating platelet function and determining
ntiplatelet drug response in patients on dual antiplatelet
reatment.
. Materials and methods
.1. Study population
The study population included 289 consecutive patients
dmitted to the Coronary Care Unit of the Azienda
spedaliero-Universitaria Careggi, University of Florence
ith diagnosis of acute MI. Acute MI was diagnosed on the
asis of an increase in creatine kinase MB isoenzyme at least
wice the upper normal limits (3.6 ng/mL), and/or elevated
Ds 196 (2008) 341–348
ardiac troponin I (cTnI) (>0.15 ng/mL) levels with at least
ne of the following: acute onset of prolonged (≥20 min)
ypical ischemic chest pain; ST-segment elevation of at least
mm in two or more contiguous electrocardiographic leads
r ST-depression of ≥0.5 mm, 0.08 s after the J point in ≥2
ontiguous leads, or T waves inversion >1 mm in leads with
redominant R waves. In 175 patients ST segment elevation
I (STEMI) and in 114 non-ST segment elevation MI
NSTEMI) was diagnosed. All patients underwent coronary
ngiography performed by the Judkins’ technique and
rimary PCI. Patients were considered to have hypertension
f they had been diagnosed as hypertensive according to
he European Society of Hypertension/European Society
f Cardiology guidelines or were taking antihyperten-
ive drugs. Dyslipidemia was defined according to the
hird report of the National Cholesterol Education Pro-
ram and diabetes according to the American Diabetes
ssociation.
The exclusion criteria included history of bleeding
iathesis, platelet count ≤100,000/mm3, hematocrit ≤30%,
reatinine ≥4.0 mg/dL, and glycoprotein (Gp) IIb/IIIa
nhibitor use.
Informed written consent was obtained from all patients
nd the study was approved by the local Ethical Review
oard.
.2. Patient characteristics
Demographic and clinical characteristics of patients are
eported in Table 1.
All patients received a loading dose of 300 mg clopi-
ogrel p.o. before the procedure and of 500 mg ASA i.v.,
ollowed by 75 mg clopidogrel and 100 mg ASA daily.
nfractioned heparin 70 IU/kg was used during procedure as
nticoagulant.
.3. Blood samplingrugs
-blockers 179 (61.9%)
Ca-antagonists 48 (16.6%)
Statins 250 (86.5%)
ACE-inhibitors 237 (82.0%)
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.4. Assessment of platelet aggregation on platelet-rich
lasma
Platelet aggregation was assessed using platelet-rich
lasma (PRP) by the turbidimetric method in a four-
hannel aggregometer (APACT 4, Helena Laboratories
taly). Platelet agonist included 2mol/L adenosine 5′
iphosphate (2M ADP), 10mol/L 10M ADP, 2g/mL
ollagen, and 0.5 mg/mL arachidonic acid (AA). PRP was
btained as supernatant after centrifugation of citrated blood
t 800 rpm for 10 min. Platelet-poor plasma (PPP) was
btained by a second centrifugation of the blood fraction
t 2500 rpm for 10 min. Light transmission was adjusted to
% with PRP and to 100% with PPP for each measurement.
urves were recorded for 6 min and analyzed according to
nternational standards. According to the Born’s method,
latelet aggregation was determined as the maximal percent
hange in light transmittance from baseline using PPP as
eference in response to different stimuli (2, 10M ADP,
A, and collagen). Platelet count was assessed at all time
oints to ensure that the degree of platelet function was not
iased by the number of platelets. The normal reference
aboratory values were: 2M ADP = 75.5 (43–92)%; 10M
DP = 76 (61–100)%; collagen = 80 (58–100)%; AA = 81.5
69–100)%.
.5. Assessment of platelet function by whole blood
latelet function analyzer (PFA100)
The PFA100 device (Dade-Behring) was used to mea-
ure platelet function at high shear conditions on whole
itrate blood according to manufacturer instructions. The
ethod determines the time to occlusion of an aperture in
membrane coated with collagen and adenosine diphos-
hate (closure time CT/ADP) or epinephrine (closure time
T/EPI).
The normal reference laboratory values were: CT/ADP =
7 (60–151) s; CT/EPI = 142 (89–204) s.
.6. Antiplatelet response
According to previous publications and to our normal lab-
ratory values, the following definitions were used:
1) Residual platelet reactivity evaluated by AA induced
platelet aggregation (AA-RPR) = AA (0.5 mg/mL)-
induced platelet aggregation ≥20% [5].
2) Residual platelet reactivity evaluated by CT/EPI PFA100
(PFA100/EPI-RPR) = CT/EPI <203 s (95th percentile of
control distribution).3) Residual platelet reactivity evaluated by ADP induced
platelet aggregation (ADP-RPR) = 10M ADP-induced
platelet aggregation ≥70% (90th percentile of control
distribution).
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.7. DNA extraction
Genomic DNA was isolated from whole blood by using
he FlexiGene DNA kit (QIAGEN, Germany).
.8. C807T, G873A and T837C GpIa gene
olymorphisms detection by electronic microchip
The three polymorphisms were analyzed by using the
anoChip Molecular Biology Workstation and the NanoChip
artridge (Nanogen). The protocol was extensively described
n a previous paper [24]. GpIa gene sequences were
btained from GeneBank (www.ncbi.nlm.nih.gov, acces-
ion number NM 002203). The used oligonucleotides for
CR and for hybridization, and the melting, annealing, and
tringency temperatures are reported in Table A (supple-
entary appendixes). The software of the system directly
ssigned the genotype to each sample.
.9. Statistical analysis
Statistical analysis was performed using the SPSS statis-
ical package Version 11.5. We tested the allele frequencies
onformed to Hardy–Weinberg equilibrium proportions by
he Chi-square test. Pairwise linkage disequilibrium (LD)
as measured by SNPAlyze software (Dynacom). Haplo-
ype reconstruction analysis was performed by using Phase
ersion 2.1 Software. Genotype and allele frequencies were
ompared between groups by Chi-square analysis. Categor-
cal variable are expressed as frequencies and percentages.
nless otherwise indicated, data are given as median val-
es and range. Comparisons of continuous variables between
atients with and without RPRs or among genotypes were
erformed by using the non-parametric Mann–Withney U-
est or the analysis of variance (Kruskal–Wallis). Multiple
ogistic regression analysis was used to estimate odds ratios
nd 95% confidence intervals (CI) of the development of AA-
PR and PFA100/EPI-RPR as a function of C807T/G873A
olymorphisms and GpIa haplotypes. All odds ratios were
djusted for age, gender and atherosclerotic risk factors, such
s hypertension, diabetes mellitus, hypercholesterolemia,
besity, and smoking. A value of p < 0.05 was chosen as the
ut-off level for statistical significance.
. Results
In Table 1 demographic and clinical characteristics of
atients are reported.
Patients, with or without RPR evaluated by both AA
nduced platelet aggregation (AA-RPR) and by PFA100 sys-
em (PFA100/EPI-RPR), were analyzed for two in-hospital
utcomes, acute intra-stent thrombosis (8 out of 289 patients,
.8%) and mortality for cardiac causes (2 out of 289
atients, 0.7%). Patients with RPR showed a higher per-
entage of acute intra-stent thrombosis (5.6% versus 1.8%
3 sclerosis 196 (2008) 341–348
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or PFA100/EPI-RPR, p = 0.09, and 5.1% versus 2.2% for
A-RPR, p = 0.22), even if it did not reach the statistical
ignificance. No significant differences for the in-hospital
ortality for cardiac causes were observed between patients
ith or without RPR evaluated by both AA-RPR and by
FA100/EPI-RPR.
C807T, G873A and T837C GpIa gene polymorphisms
ere in Hardy–Weinberg equilibrium.
The C807T and G873A polymorphisms resulted in com-
lete linkage disequilibrium.
The genotype distribution of the C807T/G873A polymor-
hisms and T837C polymorphism in the overall PCI patient
opulation are shown in Table 2. The rare allele frequency of
807T/G873A and of T873C polymorphisms was 0.360 and
.112, respectively.
The genotype distribution and allele frequencies of the
807T/G873A polymorphisms and T837C polymorphism
ere not different in relation to the two in-hospital outcomes
data not shown).
.1. GpIa polymorphisms and PRP aggregation
Platelet aggregation after different stimuli varied in the
verall patient population according to the C807T/G873A
enotypes. Carriers of the 807T/873A allele had higher
latelet aggregation values than noncarriers of the
07T/873A allele after stimuli with AA and collagen
p = 0.016 and p = 0.020, respectively) and, even if they
id not reach the statistical significance, after 2M ADP
nd 10M ADP stimuli (p = 0.071 and 0.067, respectively)
Table 2). In particular, patients with 807TT/873AA genotype
ad higher platelet aggregation values after AA and colla-
en stimuli with respect to subjects with 807CT/873GA and
07CC/873GG genotypes (Table 2).
Differences observed in platelet aggregation values after
he 4 different stimuli in the overall studied population
ccording to T837C genotypes were not statistically sig-
ificant (Table 2); however, subjects with 837TT genotype
howed higher platelet aggregation values after all the four
timuli (Table 2).
Due to the observation of higher platelet aggregation val-
es in subjects with 807TT/873AA and 837TT genotypes, we
nalyzed the effect of their genotype combinations. The com-
ination of the polymorphisms did not evidence an interaction
n inducing higher platelet aggregation values (Table 3).
.2. GpIa polymorphisms and whole blood platelet
unction by PFA100
In the whole group studied, CT/EPI values among the
ifferent C807T/G873A genotypes were statistically differ-
nt [p = 0.003; 300 (30–300) 807CC/873GG; 300 (90–300)
07CT/873GA; 300 (93–300) 807TT/873AA]. Even if the
edian CT/EPI value for 807TT/873AA genotype was
00 s, a higher number of subjects with this genotype had
T/EPI values lower than 203 (13.2% 807CC/873GG, 29.6% Tab
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Table 3
Maximal platelet aggregation after different stimuli in the overall study population according to C807T/G873A and T837C GpIa genotype combinations
C807T/G873A GpIa and T837C GpIa genotype combinations p-Value
807/873 TT/AA 837TT Others
Subjects N (%) 33 (11.5) 256 (88.5)
Aggregation according to stimulus (%)
Arachidonic Acid (0.5 mg/mL) 15.0 (5–85) 11.0 (3–91) 0.052
8
C
p
(
c
1
9
[
3
T
p
a
F
B
o
w
m
o
w
n
C
w
P
cCollagen (2g/mL) 34.0 (5–80)
ADP (2M) 27.0 (1–84)
ADP (10M) 52.0 (5–98)
07CT/873GA, 39.4% 807TT/873AA). No differences in the
T/EPI among patients carrying various T837C polymor-
hism were detected [p = 0.53; 300 (77–300) 837TT; 300
30–300) 837TC + 837CC].
No differences in the CT/ADP values among patients
arrying various C807T/G873A polymorphisms [p = 0.59;
02 (7–300) 807CC/873GG; 100 (56–300) 807CT/873GA;
8 (61–300) 807TT/873AA], or T837C polymorphism
p = 0.51; 103 (7–300) 837TT; 98 (58–300) 837TC + 837CC].
.3. GpIa polymorphisms and antiplatelet drug responseOf 289 enrolled patients, 59 (20.4%) showed AA-RPR.
he distribution of the T837C genotypes was similar in
atients with and without AA-RPR (Fig. 1, panel B), whereas
significant difference (p = 0.045) in genotype distribution
ig. 1. Genotype distribution of C873T/G873A (panel A) and T837C (panel
) GpIa gene polymorphisms in patients with and without AA-RPR.
d
t
s
F
B
R25.0 (1–99) 0.128
25.0 (3–91) 0.736
51.0 (6-94) 0.802
f C807T/G873A polymorphisms between patients with and
ithout AA-RPR was observed (Fig. 1, panel A).
Seventy-one patients out of 289 studied patients (24.6%)
et the definition of PFA100/EPI-RPR. The distribution
f the T837C genotypes was similar in patients with and
ithout PFA100/EPI-RPR (Fig. 2, panel B), whereas a sig-
ificant difference (p = 0.001) in genotype distribution of
807T/G873A polymorphisms between patients with and
ithout PFA100/EPI-RPR was observed (Fig. 2, panel A).
The groups of patients with and without AA-RPR or
FA100/EPI-RPR were homogeneous for demographic and
linical characteristics (data not shown).Forty-one patients out of 289 patients (14.2%) met the
efinition of ADP-RPR. Demographic and clinical charac-
eristics between patients with and without ADP-RPR were
imilar (data not shown). No differences between patients
ig. 2. Genotype distribution of C873T/G873A (panel A) and T837C (panel
) GpIa gene polymorphisms in patients with and without PFA100/EPI-
PR.
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Table 4
Haplotype distribution according to AA-RPR and to PFA100/EPI-RPR
Haplotype AA PFA
With RPR Without RPR With RPR Without RPR
CTG 0.480 0.545 0.434 0.563
TTA 0.435 0.343 0.484 0.323
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GCG 0.085 0.112 0.082 0.114
he C807T, T837C, and G873A SNPs in haplotypes are reported from 5′–3′
nd of the GpIa gene.
ith and without ADP-RPR were observed in C807T/G873A
807TT/873AA 34.1 and 40.3%; 807CT/873GA 58.5 and
7.6%; 807CC/873GG 7.3 and 12.1%, respectively) and
837C (CC + TC 13.9 and 22.6%; TT86.1 and 77.4%, respec-
ively) polymorphism genotype distributions.
In Table 4 the three GpIa polymorphism haplotype dis-
ribution according to AA-RPR and to PFA100/EPI-RPR
as reported. The GpIa polymorphism haplotype distribution
ccording to PFA100/EPI-RPR was significantly different in
atients with and without RPR (p = 0.0021), whereas accord-
ng to AA-RPR showed only a trend (p = 0.156). In particular,
he allele frequency of the TTA (807T/837T/873A) haplotype
as higher in patients with RPR with respect to patients with-
ut RPR (0.435 versus 0.343 for AA-RPR and 0.484 versus
.323 for PFA100/EPI-RPR).
At the multiple logistic regression analysis, the
807T/G873A GpIa gene polymorphisms resulted an inde-
endent risk factor for AA-RPR and for PFA100/EPI-RPR
Table 5). As concerns the GpIa polymorphism haplotypes, at
he multiple analysis, TTA haplotype resulted an independent
isk factor for PFA100/EPI-RPR (Table 5).
. Discussion
In this study, we investigated the role of the C807T,
873A and T837C GpIa gene polymorphisms on modulat-
ng platelet function in patients with MI undergoing PCI on
ual antiplatelet treatment. This study shows for the first time
hat the 807T/873A allele of the C807T/G873A GpIa gene
olymorphisms is an independent risk factor for the RPR on
ntiplatelet treatment, and extends, in a larger acute coronary
t
v
i
c
able 5
dds ratios for AA-RPR and PFA100/EPI-RPR according to C807T/G873A GpIa
AA-RPR
Multiple analysisa OR (95% CI) p
807T/G873A GpIa
CC/GG 1
CT/GA 1.1 (0.55–2.18) 0.800
TT/AA 3.0 (1.17–7.89) 0.022
pIa Haplotypes
CTG 1
CCG 0.9 (0.38–2.05) 0.779
TTA 1.5 (0.92–2.42) 0.106
a Adjusted for age, gender, hypertension, diabetes mellitus, hypercholesterolemias 196 (2008) 341–348
yndrome population, the observation that the 807T/873A
llele is associated with higher platelet reactivity. Moreover,
he evaluation of the three haplotypes obtained from the three
olymorphisms also shows that the 807T/837T/873A haplo-
ype is an independent risk factor for RPR on antiplatelet
reatment.
Data from the present study confirm the complete linkage
isequilibrium between 807C/873G and 807T/873A allele
n agreement with previous reports [25,26]. The prevalence
f the 807TT/873AA genotype (11.4%) was consistent with
hat reported in another Italian acute coronary syndrome
opulation (12.7%) [27], similar to those reported for Span-
sh coronary syndrome populations (from 10 to 15.5%)
22,23] and lower than that reported for Greek MI population
20.9%) [28]. Differences could be due to the low number of
atients evaluated in the previous studies. Concerning the
837C GpIa gene polymorphism, this is the first report of
ts prevalence in an Italian acute coronary syndrome popula-
ion (prevalence of the 837TC + 837CC genotypes = 21.5%).
his finding is consistent with previous data about a low
revalence of this polymorphism [21].
In addition to the evaluation of the stimulated platelet reac-
ivity by PRP aggregation, we decided to evaluate the platelet
unction by PFA100, which explores adhesion-aggregation
eactions in the presence of the other blood cells in condition
imilar to those in the circulation where platelets are exposed
o high shear stress and agonists. Therefore, the evaluation
f platelet function by PFA100 could permit us to study the
ole of GpIa gene polymorphisms in affecting the function of
he GpIa/IIa receptor in the early steps of platelet adhesion
o collagen.
Our data show that the presence of the C807T/G873A
olymorphisms, but not the T837C polymorphism, is
ssociated with higher platelet reactivity evaluated by both
RP aggregation and PFA100. Carriers of the 807T/873A
llele had significantly higher platelet aggregation values
fter AA and collagen stimuli and, even if they did not reach
he statistical significance, after ADP stimulus. Carriers of
he 807T/873A allele had also significantly shorter CT/EPI
alues by PFA100, so supporting the effect of this allele
n modulating also the early steps of platelet adhesion to
ollagen.
polymorphisms and C807T, T837C and G873A GpIa haplotypes
PFA100/EPI-RPR
Multiple analysisa OR (95% CI) p
1
2.8 (1.35–5.62) 0.005
4.1 (1.53–10.89) 0.005
1
1.0 (0.43–2.18) 0.927
2.1 (1.29–3.35) 0.003
, obesity, and smoking habit.
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In a previous study on patients undergoing PCI on dual
ntiplatelet treatment at 24 h after the procedure statistically
ignificant differences in platelet aggregation between carri-
rs and noncarriers of 807T allele upon collagen, but not ADP,
timuli was observed [22]. In a further study on CAD sub-
ects on dual antiplatelet treatment for >1 month, an increased
latelet aggregation after ADP, collagen and epinephrine
timuli in 807T allele carriers compared with noncarriers
as found [23]. Differences in ADP induced platelet aggre-
ation could be due to differences in ADP concentrations
sed for platelet aggregation induction (2M and 10M
DP present study, 6M ADP [22], and 20M ADP [23])
nd/or to the different length of dual antiplatelet treatment
24 h or >1 month). Therefore, the present findings show that
he presence of the 807T/873A allele affects not only the spe-
ific collagen induced platelet aggregation but also platelet
ggregation induced by other nonspecific stimuli, such as AA
r, even if in a mild manner, ADP. Previous functional studies
emonstrated that the two linked silent GpIa dimorphisms,
807T and G873A [20] or the three haplotypes obtained by
nalyzing C807T, T837C and G873A polymorphisms [21]
ere correlated with a variable expression of the platelet
urface 21 receptor, and that differences in the receptor
ensity directly correlate with the rate of platelet adhesion
o collagen under flow conditions [21]. Our data contribute
o demonstrate that the increased expression of 21 recep-
ors, due to the presence of 807T/873A or 807T/837T/873A
enetic profiles, determines a higher platelet reactivity inde-
endently from the applied stimuli.
At the best of our knowledge, our data show, for the first
ime, that the prevalence of the 807TT/873AA GpIa genotype
s significantly higher in patients with RPR than in patients
ithout RPR defined according to both AA-induced platelet
ggregation (AA-RPR) and CT/EPI values (PFA100/EPI-
PR (20.3% versus 9.1% and 18.3% versus 9.2%). Moreover,
e have demonstrated that the 807T/873A GpIa allele is a sig-
ificant predictor of both the AA-RPR and PFA100/EPI-RPR
both phenomena aspects of the so called ASA resistance) in
atients with MI.
The group of patients with PFA100/EPI-RPR is larger
n = 71) than that with AA-RPR (n = 59). Interestingly, among
he 25 patients with PFA100/EPI-RPR only, 19 (76%) were
eterozygous for the C807T/G873A polymorphisms (data
ot shown). This phenomenon could be due to the fact that
FA100 system is able to better explore the early steps
f platelet adhesion and aggregation to collagen and then
t is more sensible to the effect of increased number of
pIa/IIa receptors in subjects carrying the 807T/873A GpIa
llele.
Upon vessel injury, adhesion proteins, including colla-
en, become exposed to circulating blood platelets. Platelets
dhere to collagen via the GpIa/IIa receptor which is
elieved to play a major role in this process [14,16,29]. GpI-
IIa receptor density on the platelet surface is controlled
y genetic factors, including the C807T polymorphism in
he GpIa gene [21,30]. Our findings improve the knowl-s 196 (2008) 341–348 347
dge on the functional role of the C807T/G873A GpIa
olymorphisms described in previous reports [20–23] and
rovide a possible explanation on the increased risk of MI
nd stroke previously observed in 807T/873A allele car-
iers [26,28,31,32]. Moreover, our data suggest that the
807T/G873A GpIa polymorphisms are involved in mod-
lating individual response to dual antiplatelet treatment and
n particular to ASA treatment. Recently, our group provided
he first evidence that RPR, measured after primary PCI in
atients with MI, is an independent predictor of major adverse
oronary events after 1-year follow-up [11].
A limit of our study is the impossibility to finely discrim-
nate the role of the GpIa gene polymorphisms in affecting
latelet function in response to the two different treatments
ASA and clopidogrel) and to evaluate changes in platelet
unctional reactivity from the pre-treatment condition in the
ingle patient.
These results provide meaningful indication on the role of
807T/G873A GpIa polymorphisms in the real world prac-
ice of dual inhibition in acute coronary syndrome patients,
hich consider mandatory this kind of antiplatelet strategy.
ue to the fundamental clinical implications, further studies
n larger populations with an adequate follow-up are needed
n order to confirm the role of C807T/G873A GpIa gene poly-
orphisms and other polymorphisms in the same gene or
ther candidate genes as predictor of RPR and consequent
omplications.
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